Interventional Bioremediation of Microbiota in Metabolic Syndrome

Pre-Diabetes Clinical Trial

Official title:

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02730962
• Other study ID #: GI-2015-22791
• Status: Terminated
• Phase: Phase 2
• Start date: June 2016
• Est. completion date: January 2018

Study information

• Verified date: February 2023
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Provide informed consent

2. Ambulatory and community dwelling

3. Age 18 - 70 years of age

4. Able and willing to comply with the study schedule and procedures

5. Pre-diabetic with fasting blood glucose > 100 mg/dL and/or blood glucose 140-200 mg/dL 2-hours after ingestion of 75 gm glucose and/or Hemoglobin A1c > 5.7-6.5 percent

Exclusion Criteria:

1. Serious, concomitant illness that, in the opinion of the Investigator, would interfere with evaluation of safety or efficacy, or put the subject at risk of harm from study participation.

2. Known inflammatory bowel disease (Crohn's disease, ulcerative colitis, lymphocytic colitis).

3. Current abnormal liver tests that may be attributed to a cause other than non-alcoholic liver disease. Note: These exclusionary conditions may include viral hepatitis, alcoholic liver disease, hemochromatosis, Wilson's disease, medication-induced liver test abnormalities, celiac disease.

4. Renal insufficiency, defined as creatinine = 1.25 mg/dL

5. Significant alcohol use, defined as > 20 g/day in females and > 30 g/day in males for a period of 3 months within one year prior to screening.

6. Underlying chronic gastrointestinal disease that can cause diarrhea, including short bowel syndrome, diarrhea-predominant irritable bowel syndrome, malabsorption, celiac disease.

7. History of partial or complete colectomy.

8. History of malabsorptive bariatric surgery.

9. Use of insulin or hypoglycemic medications.

10. History of anaphylactic food allergies, e.g., peanuts, seafood.

11. Food intolerances and allergies, including gluten sensitivity, lactose intolerance, and intolerance of high fiber dietary content.

12. Symptomatic problems associated with intestinal gas and bloating.

13. Irritable bowel syndrome, including diarrhea-dominant, constipation-dominant, and mixed.

14. Functional GI disorder.

15. Unable to tolerate a colonoscopy.

16. Presence of an indwelling intravenous line.

17. Infection requiring antibiotics other than the conditioning antibiotics during the study period.

18. Inability to take vancomycin, neomycin, and clindamycin antibiotics prior to FMT due to known hypersensitivity or intolerance.

19. Major genetic immune dysfunction (e.g., common variable immune deficiency).

20. Acquired immune deficiencies due to infections such as HIV.

21. Immunosuppressive medications including one of the following: systemic corticosteroids, calcineurin inhibitors, thiopurines, methotrexate, biologics (e.g., anti-tumor necrosis factor drugs), cancer chemotherapy.

22. Planned use of oral probiotics while on study.

23. Planned or ongoing chemotherapy for malignancy.

24. Planned antibiotic therapy within the period of the study, e.g., perioperative antibiotics.

25. Pregnant or lactating. Female participants of child-bearing age and their partners will be counseled on contraceptive measures to prevent pregnancy during the study period.

26. History of drug or alcohol abuse in the past 2 years.

27. Currently participating in another clinical study.

28. Legally incompetent and unable to understand the study's purpose, significance and consequences, and to make decisions accordingly.

29. Presence of metal implants, such as surgical clips or pacemakers, which will preclude performance of MRI tests.

30. Inability to undergo MRI testing for any reason, e.g., claustrophobia.

Related Conditions & MeSH terms

• Metabolic Syndrome
• Pre-Diabetes
• Prediabetic State

Intervention

Drug:
• Vancomycin
Vancomycin 3 times a day for 7 days

Other:
• Placebo
Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic

Drug:
• Neomycin
Neomycin 3 times a day for 1 day
• Clindamycin
Clindamycin 3 times a day for 5 days

Procedure:
• Fecal Microbiota Transplantation
FMT conducted via colonoscopy

Locations

Country	Name	City	State
United States	University of Minnesota Medical Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Insulin Sensitivity	Insulin sensitivity measured by standard euglycemic insulin clamp.	10 weeks
Secondary	Microbiome Composition	Outcome is reported as the Shannon alpha diversity index (unitless measure) at baseline and 7 days post FMT.	7 days
Secondary	Changes in Fecal Bacterial Composition Associated With FMT Overall Antibiotic and Placebo Conditioning Groups) by Laboratory Analysis.	Microbiome composition was assessed post FMT using fecal DNA extraction and sequences. Outcome is reported as the change in relative abundance of the family Ruminococcaceae.	Baseline and 10 weeks
Secondary	Adverse Event Rates	Outcome is reported as a patient self report of adverse events over 10 weeks.	10 weeks